Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Data Boost For Intellia’s Pioneering In Vivo Gene-Editing Therapy

Next Step: Pivot To Cardiomyopathy To Take On Pfizer

Executive Summary

New data show that a high dose of Intellia’s in vivo CRISPR-Cas9 based therapy is safe and effective for up to six months, which could unlock a new era in genetic disease treatment.

You may also be interested in...



Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact

Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.

Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal

Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.

AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win

AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel